West Pharmaceutical Services (WST)
NYSE: WST · Health Care Supplies · Exton, PA
Our rating: Neutral
Neutral reaffirmed at $412.62, moderate conviction, October 30, 2026.
Breaks if: The Neutral call turns Cautious if reported organic revenue growth falls below 4% for two consecutive quarters — evidence the injectable-drug tailwind is decelerating faster than the 60x multiple can tolerate. It turns Positive if organic revenue growth reaches or exceeds 10% for two consecutive quarters, which would begin to close the visible gap between the current growth rate and the rate the implied multiple demands.
Key figures
| Market value | $27.2B |
|---|---|
| Revenue, last 12 months | $3.4B |
| Net income, last 12 months | $639M |
| Free cash flow, last 12 months | $453M |
| Price to earnings | 42.6× |
| Free cash flow yield | 1.7% |
| Dividend yield | 0.3% |
| Operating margin | 23.0% |
| Return on equity | 21.2% |
| Beta to the S&P 500 | 0.57 |
| Volatility, annualized | 44.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $875M | 8.7% | $3.02 | $150M |
| June 30, 2026 | $872M | 13.8% | $2.15 | $81M |
| March 31, 2026 | $845M | 21.0% | $1.92 | $47M |
| December 31, 2025 | $805M | 7.5% | $1.82 | $175M |
| September 30, 2025 | $805M | 7.7% | $1.92 | $134M |
| June 30, 2025 | $767M | 9.2% | $1.82 | $102M |
| March 31, 2025 | $698M | 0.4% | $1.23 | $58M |
| December 31, 2024 | $749M | 2.3% | $1.78 | $85M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.91B: Claude 55%, Gemini 55%, Mistral 48%
- Diluted earnings per share are at least $1.82: Claude 72%, Gemini 95%, Mistral 90%
- Free cash flow for the quarter is at least $0.17B: Claude 45%, Gemini 30%, Mistral 35%
11 ledger entries and 51 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.